
In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.
You're Invited!
“What's New in Schizophrenia?”
Peter Buckley, MD
May 23 at 6:00 PM (ET)
We invite you to tune in (via your computer and phone) to hear international expert on schizophrenia, Peter Buckley, MD, discuss the state-of-the-art of diagnosis and management of this challenging disorder. In a live presentation on May 23 at 6:00 PM (ET), Dr. Buckley - Dean of the Medical College of Georgia Health Sciences University - will bring you up to date and answer your questions in a live Q&A “chat.”



